tipifarnib has been researched along with beta-naphthoflavone in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (beta-naphthoflavone) | Trials (beta-naphthoflavone) | Recent Studies (post-2010) (beta-naphthoflavone) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 1,238 | 0 | 147 |
| Protein | Taxonomy | tipifarnib (IC50) | beta-naphthoflavone (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.054 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.2767 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.5149 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 5.4667 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.185 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aeri, K; Chang, M; Kim, HJ; Koh, JS; Lee, SH | 1 |
1 other study(ies) available for tipifarnib and beta-naphthoflavone
| Article | Year |
|---|---|
Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.
Topics: Alkyl and Aryl Transferases; Animals; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Microsomes, Liver; Piperazines | 2012 |